NS-080/NCNP-01
Duchenne Muscular Dystrophy (exon 45 amenable)
Key Facts
Indication
Duchenne Muscular Dystrophy (exon 45 amenable)
Phase
Phase 1/2
Status
Completed
Company
About Nippon Shinyaku
Nippon Shinyaku is a well-established, revenue-generating Japanese pharmaceutical company with a strategic focus on creating novel treatments for unmet medical needs. Its commercial success is anchored by Viltepso, an exon-skipping therapy for Duchenne muscular dystrophy, alongside other marketed products. The company leverages its research expertise to advance a pipeline spanning rare genetic diseases, oncology, and metabolic conditions, aiming for sustainable growth through both internal R&D and strategic partnerships.
View full company profile